Important Notice for Revance Therapeutics, Inc. (RVNC) Shareholders:
The Gross Law Firm, a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of shareholders of Revance Therapeutics, Inc. (RVNC) who purchased shares between February 17, 2021 and January 11, 2022. The lawsuit alleges that the company made false and misleading statements and/or failed to disclose material information during the class period.
Details of the Class Action Lawsuit:
The lawsuit alleges that Revance Therapeutics, Inc. made false and misleading statements and/or failed to disclose material information regarding the development and regulatory approval of its product, DaxibotulinumtoxinA for Injection (DAXI). The complaint alleges that the defendants failed to disclose that the company was experiencing delays in the approval process for DAXI, which would ultimately impact its revenue projections.
Impact on Shareholders:
As a result of this alleged securities fraud, Revance Therapeutics, Inc. shareholders who purchased shares during the class period have suffered significant losses. The class action seeks to recover damages on behalf of these shareholders.
How to Participate:
If you purchased shares of Revance Therapeutics, Inc. (RVNC) during the class period and wish to serve as a lead plaintiff, you may, no later than April 26, 2025, request that the court appoint you as lead plaintiff by contacting The Gross Law Firm. Shareholders have until April 26, 2025 to ask the court to appoint them as lead plaintiff.
Impact on the World:
The implications of this class action lawsuit extend beyond just Revance Therapeutics, Inc. and its shareholders. The lawsuit highlights the importance of transparency and honesty in the business world. Companies have a responsibility to disclose material information to their investors in a timely and accurate manner. Failure to do so can result in significant financial losses for shareholders and damage to the company’s reputation.
Conclusion:
If you are a shareholder of Revance Therapeutics, Inc. and purchased shares during the class period, it is important that you take action. Contact The Gross Law Firm to learn more about your rights and potential recovery. This lawsuit serves as a reminder that companies must be transparent and honest with their investors, and that shareholders have the right to hold them accountable when they fail to do so.
- Revance Therapeutics, Inc. (RVNC) shareholders who purchased shares between February 17, 2021 and January 11, 2022 are encouraged to contact The Gross Law Firm.
- The class action lawsuit alleges that the company made false and misleading statements and/or failed to disclose material information regarding the development and regulatory approval of its product, DaxibotulinumtoxinA for Injection (DAXI).
- Shareholders have until April 26, 2025 to ask the court to appoint them as lead plaintiff.
- The lawsuit highlights the importance of transparency and honesty in the business world.
